Strategic partnerships are a fundamental part of ABL’s strategy to maximize the impact of its technology and build long-term value. ABL partners with pharmaceutical and biotechnology companies to enhance drug discovery by providing considerable inputs either through licencing of developed technologies or co-developing them with partners. ABL also partners with platform companies to leverage complementary technologies. Given the significant value created for its partners, ABL expects to share in both the financial and intellectual property value generated through these alliances.

In addition to pharmaceutical collaborations, ABL welcomes alliances with companies that have complementary intellectual property, technology or expertise. Such companies might include those with novel phytopharmaceuticals, intellectual property, informatics capabilities, compound libraries, synthetic chemistry capabilities, or biological platform expertise.

Products and formulations:

ABL has developed over 150 formulations both in therapeutics as well as in nutrition, for the pharma industry. Apart from offering various finished products from its three manufacturing facilities, ABL also welcomes opportunities for strategic alliances with pharma and marketing companies.